Price
No data yet.
Social Signal Score
Revenue
$0.00-100.00%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Luis C. Pena
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 48
- Beta
- 0.96
- Country
- US
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- 9.40
Financials
EVMN has only 9 quarterly periods on file — the charts below show the full history available.
Revenue
$0.00-100.0%Net Income
$-32.25MEBITDA
$-34.34MFree Cash Flow
$-20.50MEPS (diluted)
$-0.89Shares Outstanding (diluted)
36.14M+20.1%Operating Expenses
$34.90MCash & Debt
$200.79MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $13.00M | $-68.87M | $-2.18 |
| 2024 | $7.00M | $-66.81M | $-2.27 |
| 2023 | $5.00M | $-34.05M | $-1.13 |
Valuation
EVMNhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+50.00%Social Signal Score
Mentions (2)
- Newsbenzinga.com·5h ago·Neutral
Evommune Halts Atopic Dermatitis Program Following Trial Failure On Tuesday, clinical-stage biotechnology company Evommune Inc. (NYSE:EVMN) announced topline results from its dose-ranging Phase 2b trial assessing oral EVO756 for moderate-to-severe atopic dermatitis.
View source ↗ - Newsreuters.com·19h ago·Negative
Evommune scraps eczema drug after trial miss, shares plunge Evommune said on Tuesday it will not advance its experimental skin disease drug after it failed to meet the main goal in a mid-stage trial, sending its shares down 24% in aftermarket trading.
View source ↗
Earnings
Fri, Oct 16(in 5 weeks)
Consensus estimate $-0.82 per share
Typical surprise -33.9% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$-0.89 vs $-0.66miss
- Thu, May 7$-0.64 vs $-0.83beat
- Thu, Mar 5$-1.43 vs $-0.82miss
- Thu, Dec 11$-8.07 vs $-0.84miss
- Thu, Oct 9$-0.45 vs $-6.08beat
Estimates and results for EVMN via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.